{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T19:52:54Z","timestamp":1721591574449},"reference-count":30,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1536\/ihj.16-226","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T22:13:13Z","timestamp":1495491193000},"page":"378-384","source":"Crossref","is-referenced-by-count":10,"title":["Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients"],"prefix":"10.1536","volume":"58","author":[{"given":"Kiyoshi","family":"Takasu","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Negoro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Yatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Hiki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rosenhek R, Binder T, Porenta G, <i>et al<\/i>. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343: 611-7.","DOI":"10.1056\/NEJM200008313430903"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Carabello BA. Evaluation and management of patients with aortic stenosis. Circulation 2002; 105: 1746-50.","DOI":"10.1161\/01.CIR.0000015343.76143.13"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 2004; 110: 1180-2.","DOI":"10.1161\/01.CIR.0000140722.85490.EA"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316-26. (Review)","DOI":"10.1161\/CIRCULATIONAHA.104.486738"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Otto CM, Prendergast B. Aortic-valve stenosis--from patients at risk to severe valve obstruction. N Engl J Med 2014; 371: 744-56. (Review)","DOI":"10.1056\/NEJMra1313875"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Asimakopoulos G, Edwards MB, Taylor KM. Aortic valve replacement in patients 80 years of age and older: survival and cause of death based on 1100 cases: collective results from the UK Heart Valve Registry. Circulation 1997; 96: 3403-8.","DOI":"10.1161\/01.CIR.96.10.3403"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Moura LM, Ramos SF, Zamorano JL, <i>et al<\/i>. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49: 554-61.","DOI":"10.1016\/j.jacc.2006.07.072"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cowell SJ, Newby DE, Prescott RJ, <i>et al<\/i>. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-97.","DOI":"10.1056\/NEJMoa043876"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Webb JG, Wood DA. Current status of transcatheter aortic valve replacement. J Am Coll Cardiol 2012; 60: 483-92. (Review)","DOI":"10.1016\/j.jacc.2012.01.071"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother 2011; 12: 961-76. (Review)","DOI":"10.1517\/14656566.2011.567267"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Semba H, Kinugawa K, Takeda N, <i>et al<\/i>. Preliminary report of tolvaptan treatment in Japanese patients with heart failure. Int Heart J 2012; 53: 72-4.","DOI":"10.1536\/ihj.53.72"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nishizaki Y, Yamagami S, Sesoko M, Yamashita H, Daida H. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide. J Cardiol Cases 2013; 8: 151-4.","DOI":"10.1016\/j.jccase.2013.07.005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Imamura T, Kinugawa K, Fujino T, <i>et al<\/i>. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240-9.","DOI":"10.1253\/circj.CJ-14-0244"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Konstam MA, Gheorghiade M, Burnett JC Jr, <i>et al<\/i>. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.","DOI":"10.1001\/jama.297.12.1319"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Toda H, Nakamura K, Nakahama M, <i>et al<\/i>. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size. J Cardiol 2016; 67: 177-83.","DOI":"10.1016\/j.jjcc.2015.04.017"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Watanabe K, Dohi K, Sugimoto T, <i>et al<\/i>. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012; 60: 462-9.","DOI":"10.1016\/j.jjcc.2012.09.002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sato Y, Dohi K, Watanabe K, <i>et al<\/i>. Combination of urinary sodium\/creatinine ratio and plasma brain natriuretic peptide level predicts successful tolvaptan therapy in patients with heart failure and volume overload. Int Heart J 2016; 57: 211-9.","DOI":"10.1536\/ihj.15-330"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bhatt PR, McNeely EB, Lin TE, Adams KF, Patterson JH. Review of tolvaptan\u2019s pharmacokinetic and pharmacodynamic properties and drug interactions. J Clin Med 2014; 3: 1276-90. (Review)","DOI":"10.3390\/jcm3041276"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Udelson JE, Orlandi C, Ouyang J, <i>et al<\/i>. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-5.","DOI":"10.1016\/j.jacc.2008.08.013"},{"key":"20","unstructured":"20. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: time for a new approach? Circ Heart Fail 2014; 7: 531-5."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Smith GL, Lichtman JH, Bracken MB, <i>et al<\/i>. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-96. (Review)","DOI":"10.1016\/j.jacc.2005.11.084"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006; 27: 1216-22.","DOI":"10.1093\/eurheartj\/ehi859"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takagi A, Iwama Y, Yamada A, Aihara K, Daida H. Estimated glomerular filtration rate is an independent predictor for mortality of patients with acute heart failure. J Cardiol 2010; 55: 317-21.","DOI":"10.1016\/j.jjcc.2009.12.005"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Belziti CA, Bagnati R, Ledesma P, Vulcano N, Fern\u00e1ndez S. Worsening renal function in patients admitted with acute decompensated heart failure: incidence, risk factors and prognostic implications. Rev Esp Cardiol 2010; 63: 294-302. (English, Spanish)","DOI":"10.1016\/S1885-5857(10)70062-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Matsue Y, Suzuki M, Seya M, <i>et al<\/i>. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013; 61: 169-74.","DOI":"10.1016\/j.jjcc.2012.08.020"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kimura K, Momose T, Hasegawa T, <i>et al<\/i>. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 2016; 67: 399-405.","DOI":"10.1016\/j.jjcc.2015.09.020"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev 2007; 25: 1-13. (Review)","DOI":"10.1111\/j.1527-3466.2007.00001.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273-8.","DOI":"10.1152\/ajprenal.00195.2005"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Schrier RW, Gross P, Gheorghiade M, <i>et al<\/i>. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.","DOI":"10.1056\/NEJMoa065181"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gheorghiade M, Gottlieb SS, Udelson JE, <i>et al<\/i>. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97: 1064-7.","DOI":"10.1016\/j.amjcard.2005.10.050"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_16-226\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T23:04:08Z","timestamp":1569366248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_16-226\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.16-226","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}